Biologic medicines in dermatology    

FOI REFERENCE: 24084   FOI DATE: 3^rd May 2024   

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira                        0
• Adalimumab Biosimilar                       55
• Apremilast                                          *
• Bimekizumab                                      0
• Brodalumab                                        *
• Certolizumab                                      *
• Deucravacitinib                                   0
• Dimethyl fumarate                              0
• Etanercept – Enbrel                           *
• Etanercept Biosimilar                         0
• Guselkumab                                       7
• Infliximab – Remicade                        0         
• Infliximab Biosimilar                           0
• Ixekizumab                                         *
• Risankizumab                                     *
• Secukinumab                                     15
• Tildrakizumab                                     17
• Ustekinumab                                      25

Q2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:

• Adalimumab – Humira                        0
• Adalimumab Biosimilar                       *
• Bimekizumab                                      0
• Certolizumab                                      0
• Infliximab – Remicade                        0
• Infliximab Biosimilar                           0
• Secukinumab                                     0
• Ustekinumab                                      0

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018